Shares of Sarepta Therapeutics were on the rise after the Food and Drug Administration (FDA) suddenly approved the company’s second Duchenne muscular dystrophy (DMD) drug. Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. … Continue reading “The FDA Suddenly Approves This Drug From Sarepta Therapeutics”
